CD BioSciences Introduces Randomization Plan Design Services for Clinical Research
CD BioSciences introduces Randomization Plan Design services for various clinical trials to the scientific and research communities.
- (1888PressRelease) July 18, 2021 - CD BioSciences, a provider of comprehensive clinical trial services with over a decade of experience, now introduces Randomization Plan Design services for various clinical trials to the scientific and research communities, helping them to develop a clear and simple randomization plan to ensure its unpredictability and balance and thus reduce or eliminate bias.
In clinical trials, randomization is very important, as it is a sampling method and commonly used in randomized controlled trials in experimental research, in which the research participants are assigned by chance, rather than by choice, to either the experimental group or the control group. Randomization plan design is to set out an appropriate randomization plan in order that each treatment is equally likely to be assigned to any given experimental unit.
Scientists at CD BioSciences are experienced in various types of study design in many different clinical areas such as central nervous system, cardiovascular, immunology, pediatric, oncology and hematology. Its experts will help clients to develop a clear and simple randomization plan to ensure its unpredictability and balance and thus reduce or eliminate bias. And the randomization plan design services for the various clinical trials include a comprehensive series of services such as balance keeping in numbers, prognostic factors balancing, and cost reduction.
For services of balance keeping in numbers, although treatment assignment is completely unpredictable, using the random number generator is simple and easy to implement. For example, in small trials, even if treatment is balanced at the end of a trial, it may not be balanced at some time during the trial. Considering this problem, CD BioSciences has designed to divide potential patients into m blocks of size 2n, randomize each block such that n patients are allocated to A and the other n patients to B, and then choose the blocks randomly. It will ensure equal treatment allocation within each block if the complete block is used.
"We are very excited to launch our randomization plan design services coupled with our other biostatistics services, and we'll work closely with our customers' team to fulfill their needs and address any challenges they might meet in the workflows." said Helen James, senior scientist at CD BioSciences. "We can guarantee the confidentiality and sensitivity of your data, and we're committed to providing you with timely and high-quality deliverables, and at the same time, cost-effective, complete and concise reports are also ensured."
For more detailed information on randomization plan design services or other related services, please visit CD BioSciences at https://www.cd-biosciences.com.
About CD BioSciences
Based in the US, CD BioSciences offers a full range of clinical trial consulting, design, conduction, management, reporting and analysis services to advance clients' clinical trial development needs. Its clinical trial services focus on the entire clinical trial lifecycle including bioanalytical lab testing, clinical pharmacology, first-in-human (FIH), proof of concept (POC), early phase trials, phase IIa trials, phase IIb-III trials, phase IIIb-IV trials, CDM analysis and reporting. CD BioSciences has provided professional support to local, national, and international clients.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam